Table of Contents
What is the latest Corona Virus Update?
- Coronavirus Update Today, the U.S. Food and the Drug Administration (FDA) issued guidelines for medical product developers, specifically covering vaccines, diagnostics, and therapeutics.
- To address the emergence and possible future emergence of variants SARS-CoV-2, the virus that causes COVID-19.
- Therapies and vaccines available to fight this virus is the Coronavirus Update .
- We remain committed to bringing these life-saving products to the front lines.
- As with any evolving situation, the FDA will continually monitor the status, update the vaccinated to prevent COVID-19.
- Follow Coronavirus Update essential health measures such as washing hands, wearing a mask, and maintaining social distance.
- Currently, available information suggests that FDA-cleared vaccines remain effective in protecting the American public against now circulating SARS-CoV-2 variants.
- However, suppose variants of SARS-CoV-2 appear in the U.S. that are moderately or resistant to the antibody response elicited by the current generation of COVID-19 vaccines.
- In that case, it may be necessary to tailor the vaccines to the variant.
- The updated guide presents the FDA’s scientific recommendations for licensed vaccine modifications.
- For example, the FDA expects that the manufacturing information will generally remain the same for a licensed vaccine and a modified candidate vaccine from the same manufacturer.
- What’s more, the guide describes the FDA’s recommendations for safety evaluations that support a EUA for a modified vaccine.
- Finally, the principle states that further discussion will be necessary to decide whether, in the future, modified COVID-19 vaccines for clinical uses.
Testing for COVID-19
- The FDA has released a new guide for test developers, Policy for Evaluating the Impact of Viral Mutations on COVID-19 Tests.
- The guide provides information on evaluating the potential impact of emerging and future viral genetic mutations.
- Which may underlie viral variants, on COVID-19 testing.
- The FDA identified some tests that are known to be affected by occurring viral mutations, although, at this time, the impact does not appear to be significant.
- To address the impact of emerging SARS-CoV-2 variants on developing monoclonal antibody products targeting the virus, the FDA has published new guidance, Development of SARS-CoV-2
- Targeting Monoclonal Antibody Products, Including the attention to the impact of emerging variants, during the public health emergency of COVID-19.
- The FDA has also revised a second guideline that more broadly covers drugs and biologics for COVID-19.
- COVID-19: Developing Drugs and Biologics for Treatment or Prevention.
- The new guidance provides recommendations for developers of monoclonal antibodies targeting SARS-CoV-2 during the COVID-19 public health emergency.
- Monoclonal antibodies are proteins made in laboratories that mimic the immune system’s ability to fight harmful pathogens, such as viruses, such as SARS-CoV-2.
- The FDA is aware that few licensed antibodies are less active against some of the SARS-CoV-2 variants that have emerged.
- This guide provides recommendations on efficient approaches for the generation of non-clinical, clinical, and chemistry data, manufacturing.
- Controls that could support an AUS for monoclonal antibody products that may be effective against emerging variants.
- The revised guidance covering drugs and biologics more broadly, initially published in May 2020.
- Outlines the current FDA recommendations regarding phase 2 and 3 clinical trials for drugs and biologics in development to treat or prevent COVID-19
- Patient population, trial design, efficacy endpoints, safety considerations, statistical considerations for such trials and more.
- Address the changing environment of COVID-19 drug development, including the emergence of SARS-CoV-2 variants and the availability of licensed COVID-19 vaccines.
- With these guidelines, the FDA urges developers of drugs or biologics targeting SARS-CoV-2
- To monitor genomic databases for emerging SARS-CoV-2 variants continually
- To phenotypically evaluate any specific variant targeting the product that is becoming prevalent or that could potentially affect your business.
- The FDA, an agency of the United States Department of Health and Human Services
- Protects the public health by ensuring the protection, efficacy and safety of veterinary.
- Like human drugs, vaccines, and other biological products intended for human use.
- The agency is also responsible for protecting and safety of our national food supply, cosmetics, dietary supplements, products that emit electronic radiation, and the regulation of tobacco products.